- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
VIDEO: Drops for presbyopia correction show promise in Phase 3 safety studies
At the recent Women in Ophthalmology Summer Symposium, held in Monterey, California, Cathleen M. McCabe, MD, outlined how pilocarpine HCl Ophthalmic Solution 1.25%, the first and only FDA-approved eye drop to treat presbyopia could offer an opportunity for patients looking for spectacle independence.
Cathleen McCabe, MD, recently discussed her presentation at the Women in Ophthalmology Summer Symposium, titled "GEMINI 1 and 2 pooled Phase 3 safety and efficacy: AGN-190584 primary and key secondary endpoints"
McCabe discussed the trial, its results and the hope these drops could have for patients diagnosed with presbyopia.
Allergan, a subsidiary of AbbVie, announced last fall that the FDA had approved pilocarpine HCl Ophthalmic Solution 1.25% (Vuity) for the treatment of adult patients with presbyopia.
